Tobii provides eye tracking technology for NovaSight’s groundbreaking pediatric Amblyopia treatment

Long-standing Tobii client NovaSight receives prestigious medical journal verification for CureSight, an eye tracking based treatment for Amblyopia (lazy eye).

NovaSight is a medical device company in the field of eye care specializing in comprehensive solutions in diagnostic, therapeutic, and prevention through advanced eye tracking technology. CureSight™, the company’s flagship product, is an eye tracking based device for remote digital treatment of amblyopia (lazy eye). CureSight, which received FDA-clearance in October 2022, has been showcased in a study published in the American Journal of Ophthalmology. The findings of this study indicate that patients undergoing treatment with CureSight, experienced significant long-term visual and stereo acuity improvements. This milestone further supports the adoption of CureSight in the US, Italy and Israel, which since its launch in early 2023 has been embraced by over 300 eye care providers who have referred more than 800 patients to the treatment.

Tobii maintains a long-standing partnership with NovaSight. Aside from collaborating on the eye tracking components of the CureSight device, Tobii supplies eye tracking technology to NovaSight’s vision diagnostics device - EyeSwift®PRO.

“We are glad that that NovaSight has reached this important milestone for their innovative treatment, and we are very proud to be part of their journey”, said Emma Bauer, Senior Vice President, Integrations at Tobii. “CureSight is yet another great example of how eye tracking technology can enable innovation in so many different challenges and for so many different use cases.”

"Through our partnership with Tobii, we're transforming the landscape of vision care by integrating cutting-edge eye tracking technology into NovaSight's solutions, revolutionizing how we diagnose and treat vision disorders.", said Ran Yam, NovaSight's CEO and Co-Founder.

An innovative treatment for a widespread condition

It is estimated that 3 percent of the world’s population suffer from Amblyopia. In the US alone, the estimate is roughly 10 million people. The treatment with CureSight device is carried out while the child watches any streamed content of their choice on a user-friendly all-in-one computer from the comfort of their home. Using complex algorithms and eye-tracking technology, CureSight constantly blurs the center of the image that is presented to the strong eye through real-time image-processing while the image presented to the lazy eye remains sharp. This encourages the brain to complete the image's fine details from the amblyopic eye and improves acuity while developing stereoacuity and 3D perception as the eyes learn to work together as a team.

The benefits of using this kind of treatment compared to traditional eye patching is an increased treatment adherence due to its unobtrusive nature. Improved quality of life during the treatment period, which could encourage a higher percent of children diagnosed with Amblyopia to undergo treatment, are other benefits.

For more information, please contact:

Rasmus Löwenmo Buckhöj, Head of Communications, Tobii AB, +46 (0)73 327 87 64, email: rasmus.lowenmobuckhoj@tobii.com

About Tobii

Tobii is the global leader in eye tracking and pioneer of attention computing. We are on a mission to improve the world with technology that understands human attention and intent. Creating tech for a better future, our technologies and solutions apply to areas such as behavioral studies and research, healthcare, education and training, gaming, extended reality, automotive, and many more. Tobii's eye tracking is used by thousands of enterprises, universities, and research institutes around the globe. Headquartered in Sweden, Tobii is listed on Nasdaq Stockholm (TOBII). For more information: www.tobii.com

About NovaSight

Established in 2016, NovaSight is a growing medical device company with a mission to prevent vision impairments using eye tracking based technology in novel diagnostic, therapeutic, and preventive solutions, among other also designed for the unique needs of children. NovaSight offers two flagship products, both ideally positioned for remote home treatment and diagnostics: The CureSight™ system is an FDA cleared eye-tracking-based device for treatment of amblyopia designed to replace traditional eye patching. The EyeSwift®PRO system is a comprehensive vision-assessment device that accurately and objectively screens for multiple vision impairments within seconds. Additional pipeline products include the TrackSight™ digital solution for myopia (short-sightedness) control, targeted to provide an affordable and accessible solution to help combat the myopia global epidemic.